NCCN guidelines® insights chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017: Featured updates to the NCCN guidelines

William G. Wierda, Andrew D. Zelenetz, Leo I. Gordon, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, John C. Byrd, Paolo Caimi, Luis E. Fayad, Richard I. Fisher, Martha J. Glenn, Thomas M. Habermann, Nancy Lee Harris, Francisco Hernandez-Ilizaliturri, Richard T. Hoppe, Steven M. Horwitz, Mark S. Kaminski, Christopher R. Kelsey, Youn H. KimSusan Krivacic, Ann S. LaCasce, Michael G. Martin, Auayporn Nademanee, Pierluigi Porcu, Oliver Press, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Kenneth Roberts, Ayman A. Saad, Erin D. Snyder, Lubomir Sokol, Lode J. Swinnen, Julie M. Vose, Joachim Yahalom, Mary A. Dwyer, Hema Sundar

Research output: Contribution to journalReview articlepeer-review

51 Scopus citations

Abstract

Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different manifestations of the same disease and managed in much the same way. The advent of novel CD20 monoclonal antibodies led to the development of effective chemoimmunotherapy regimens. More recently, small molecule inhibitors targeting kinases involved in a number of critical signaling pathways and a small molecule inhibitor of the BCL-2 family of proteins have demonstrated activity for the treatment of patients with CLL/SLL. These NCCN Guidelines Insights highlight important updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for CLL/ SLL for the treatment of patients with newly diagnosed or relapsed/refractory CLL/SLL.

Original languageEnglish (US)
Pages (from-to)293-311
Number of pages19
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume15
Issue number3
DOIs
StatePublished - Mar 1 2017

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'NCCN guidelines® insights chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017: Featured updates to the NCCN guidelines'. Together they form a unique fingerprint.

Cite this